Tim Smith

The house dust mite allergen extract was approved by the FDA for treating adolescents with immunotherapy.

Recent findings indicated that patients with new-onset psoriasis may see positive results from switching to secukinumab treatment.

New research connected dupilumab levels to OSD in atopic dermatitis patients, indicating a contribution to the development of the condition.

This recent analysis highlighted an association between anxiety disorder and psoriasis in both children and adult patients.

New research on updadacitinib’s use for atopic dermatitis patients suggests the drug may be effective for hand eczema.

A recent study on allergies to methylchloroisothiazolinone or methylisothiazolinone, with findings suggesting that European regulations may have diminished sensitivity rates.

A discussion with Henry Lim, MD, during an interview segment in which he described photoprotection measures for various skin phenotypes and his outlook on future research.

New research indicates that rheumatoid arthritis patients switching to biosimilars to adalimumab may see improved outcomes by sticking with their original treatment.

An interview segment on HCPLive with James Del Rosso, DO, in which he explores key highlights from his presentation at the 2023 Winter Clinical conference.

An HCPLive interview with Henry Lim, MD, during which he describes the differing needs of various skin types and the differences in sunscreen regulations.

An interview segment with Henry Lim, MD, on his presentation from Winter Clinical regarding different photoprotection measures for different phenotypes.

In a segment of his HCPLive interview regarding his Winter Clinical presentation, James Del Rosso, DO, highlighted several points about acne and rosacea treatment.

This segment of Raj Chovatiya’s interview with HCPLive, a discussion was conducted regarding facts about abrocitinib for atopic dermatitis treatment.

During an HCPLive interview on his presentation at Winter Clinical, Raj Chovatiya discussed the use of abrocitinib on atopic dermatitis patients.

In a Q&A interview with Glynis Ablon, the dermatologist described highlights from her recent Winter Clinical presentation on new devices for clinical practice.

An overview of some of the biggest articles in the dermatology field covered this week, including new breakthroughs in research.

An interview segment featuring Lal’s experiences treating epidermolysis bullosa as well as his opinions on treatment and management.

An interview with Karan Lal on his experiences treating patients facing the rare condition known as epidermolysis bullosa.

An FDA announcement on this topical gene therapy for DEB pushes back the PDUFA date to May of this year, accompanying a regulatory update.

A recent study demonstrated that a combined treatment of topical corticosteroids and lebrikizumab led to reduced atopic dermatitis severity compared to the non-lebrikizumab group.

In her interview with HCPLive, Armstrong spoke on new data presented at Fall Clinical Dermatology on bimekizumab, deucravacitinib, and upadacitinib.

The sex differences, as well as other demographic differences, between GPP patients were assessed in a recent research letter.

A letter to the editor from China explored the various types of reactions to two types of vaccines for COVID-19.

A new study from Denmark explored the ineffectiveness associated with dupilumab in certain regions of the body after long-term examination.

A literature review summarized research on sesame allergies as the FDA begins labeling sesame as a major food allergen.

A set of highlights from some of the more impactful research and data covered this past week in the dermatology field, covering breakthroughs in research and advanced treatment options.

New research identified gene-corrected autologous keratinocyte grafts as useful for treating recessive DEB patients.

New research into students’ understanding of the dermatology field suggests greater knowledge and exposure may instill greater appreciation for it among medical students.

New data suggests occupational exposure to certain melanocytotoxic chemicals may lead to vitiligo.

In a summary of a symposium from the 2021 EADV Congress, the writers describe patients’ difficulties in living with psoriasis and adhering to treatments.